Core Viewpoint - The article highlights the significant financial performance of BeiGene, showcasing its successful global business strategy and marking a milestone in the profitability of Chinese innovative pharmaceutical companies in the oncology sector [2]. Financial Performance - In Q3 2025, BeiGene reported total revenue of $1.4 billion, a 41% increase year-over-year, achieving a historical high for the same period. The net profit was 689 million yuan, marking a turnaround from losses [1]. - For the first three quarters of 2025, revenue reached 27.595 billion yuan, up 44.2% year-over-year, with a net profit of 1.139 billion yuan, also a turnaround from losses [1]. Product Performance - The BTK inhibitor, Zanubrutinib, achieved global sales of $1.039 billion in the quarter, a 51% increase year-over-year, entering the "blockbuster" drug category and becoming the highest-grossing product in its class [2]. - In the U.S. market, Zanubrutinib sales reached $739 million, a 47% increase year-over-year, with a growing market share and a leading position in new patient acquisition [2]. - In Europe, Zanubrutinib's sales surged to $163 million, a 68% increase year-over-year, with full inclusion in health insurance in major countries like Germany, Italy, and France [2]. Regulatory Approvals and Clinical Trials - Zanubrutinib is approved for five indications, including chronic lymphocytic leukemia and mantle cell lymphoma, with ongoing expansion into new indications such as primary membranous nephropathy [3][4]. - The company has also made significant progress with its PD-1 product, Tislelizumab, which received EU approval for use in non-small cell lung cancer [4]. Future Outlook - BeiGene has raised its revenue guidance for the year from $5-5.3 billion to $5.1-5.3 billion, driven by the continued growth of Zanubrutinib and its expansion in Europe and other regions [7]. - The company anticipates several important developments in 2026, including potential orphan drug designation for Zanubrutinib in Japan and further clinical trials for its other products [7][8]. - The revenue potential for BeiGene remains substantial, with upcoming data readouts expected to drive future growth [9].